- Home
- GEG vs IMMX Comparison
GEG vs IMMX Comparison
Compare GEG & IMMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GEG
- IMMX
- Stock Information
- Founded
- GEG 1994
- IMMX 2014
- Country
- GEG United States
- IMMX United States
- Employees
- GEG N/A
- IMMX N/A
- Industry
- GEG Computer Software: Prepackaged Software
- IMMX Medicinal Chemicals and Botanical Products
- Sector
- GEG Technology
- IMMX Health Care
- Exchange
- GEG Nasdaq
- IMMX Nasdaq
- Market Cap
- GEG 54.7M
- IMMX 54.9M
- IPO Year
- GEG N/A
- IMMX 2021
- Fundamental
- Price
- GEG $2.15
- IMMX $1.95
- Analyst Decision
- GEG
- IMMX Strong Buy
- Analyst Count
- GEG 0
- IMMX 1
- Target Price
- GEG N/A
- IMMX $7.00
- AVG Volume (30 Days)
- GEG 20.1K
- IMMX 398.8K
- Earning Date
- GEG 05-07-2025
- IMMX 06-10-2025
- Dividend Yield
- GEG N/A
- IMMX N/A
- EPS Growth
- GEG N/A
- IMMX N/A
- EPS
- GEG N/A
- IMMX N/A
- Revenue
- GEG $19,626,000.00
- IMMX N/A
- Revenue This Year
- GEG N/A
- IMMX N/A
- Revenue Next Year
- GEG N/A
- IMMX N/A
- P/E Ratio
- GEG N/A
- IMMX N/A
- Revenue Growth
- GEG 64.34
- IMMX N/A
- 52 Week Low
- GEG $1.70
- IMMX $1.26
- 52 Week High
- GEG $2.20
- IMMX $3.00
- Technical
- Relative Strength Index (RSI)
- GEG 67.50
- IMMX 48.06
- Support Level
- GEG $1.98
- IMMX $1.87
- Resistance Level
- GEG $2.20
- IMMX $3.00
- Average True Range (ATR)
- GEG 0.10
- IMMX 0.25
- MACD
- GEG 0.01
- IMMX -0.01
- Stochastic Oscillator
- GEG 83.30
- IMMX 11.50
About GEG Great Elm Group Inc.
Great Elm Group Inc operates as an alternative asset manager focused on growing a scalable and diversified portfolio of long-duration and permanent capital vehicles across credit, real estate, specialty finance, and other alternative strategies. Along with its subsidiaries, it manages Great Elm Capital Corp, a publicly traded business development company, and Monomoy Properties REIT, LLC, an industrial-focused real estate investment trust, in addition to other investments.
About IMMX Immix Biopharma Inc.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.